Biomedical research is increasingly shifting from empirical observation toward a mechanistic understanding of disease biology and therapeutic response. In this context, clinical pharmacology has evolved into an integrative discipline that links drug action to disease mechanisms across molecular, cellular, and systems levels. Central to this transformation are pharmacokinetic–pharmacodynamic (PK–PD) modeling, biomarker-based assessment, and systems pharmacology approaches, which together provide a quantitative framework for interpreting drug exposure, target engagement, and downstream biological effects. These approaches support a mechanistic understanding of dose–response relationships and facilitate more rational dose selection beyond traditional empirical strategies. The integration of dynamic biomarkers has further advanced the field by enabling real-time assessment of pathway activity and disease progression, particularly in heterogeneous disorders such as diabetes and immune-mediated metabolic diseases. For example, the clinical development of SGLT2 inhibitors such as empagliflozin illustrates how mechanistic PK–PD modeling and biomarker integration can reveal therapeutic effects extending beyond glycaemic control, including cardiovascular and renal benefits that were not predicted by glucose lowering alone. Early-phase clinical studies supported by model-informed drug development frameworks also allow earlier evaluation of mechanistic hypotheses in humans and improve the prediction of interindividual variability in therapeutic response and toxicity. In parallel, the bidirectional exchange of information between preclinical and clinical research through forward and reverse translation contributes to model refinement and strengthens predictive accuracy in drug development. Collectively, these advances position clinical pharmacology as a mechanistic framework within translational medicine, bridging experimental biology and clinical therapeutics. This evolving paradigm supports the transition toward precision and mechanism-guided drug development, where therapeutic strategies are increasingly informed by causal biological pathways rather than empirical associations.